{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:47:14Z","timestamp":1772160434483,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,10,18]],"date-time":"2012-10-18T00:00:00Z","timestamp":1350518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2013,1]]},"abstract":"Abstract<\/jats:title>\n \n Aim<\/jats:title>\n \n To determine the rate ratio of neuropsychiatric hospitalizations in new users of varenicline compared to new users of nicotine replacement therapy (\n NRT<\/jats:styled-content>\n ) patch in the\n M<\/jats:styled-content>\n ilitary\n H<\/jats:styled-content>\n ealth\n S<\/jats:styled-content>\n ystem (\n MHS<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Design, setting and participants<\/jats:title>\n \n Varenicline (\n n<\/jats:italic>\n \u2009=\u200919\u2009933) and\n NRT<\/jats:styled-content>\n patch (\n n<\/jats:italic>\n \u2009=\u200915\u2009867) users who initiated therapy from 1\n A<\/jats:styled-content>\n ugust 2006 to 31\n A<\/jats:styled-content>\n ugust 2007 within the\n MHS<\/jats:styled-content>\n were included in this retrospective cohort study. After matching according to propensity scores, 10\u2009814 users remained in each cohort. The study population included those with and without a history of neuropsychiatric disease.\n <\/jats:p>\n <\/jats:sec>\n \n Measurements<\/jats:title>\n \n Patients were followed for neuropsychiatric hospitalizations defined by primary neuropsychiatric discharge diagnosis using\n ICD<\/jats:styled-content>\n \u20109 codes from in\u2010patient administrative claims. Hazard ratios (\n HR<\/jats:styled-content>\n ) and 95% confidence intervals (\n CI<\/jats:styled-content>\n ) were estimated after propensity score matching on exposure for socio\u2010demographic factors, health\u2010care utilization, comorbidities, medication history and neuropsychiatric history.\n <\/jats:p>\n <\/jats:sec>\n \n Findings<\/jats:title>\n \n There was no increase in the rate of neuropsychiatric hospitalizations in patients treated with varenicline compared to\n NRT<\/jats:styled-content>\n patch when followed for 30 days (propensity\u2010score matched\n HR<\/jats:styled-content>\n \u2009=\u20091.14, 95%\n CI:<\/jats:styled-content>\n \u20090.56\u20132.34). Results were similar after 60 days of follow\u2010up.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n There does not appear to be an increase in neuropsychiatric hospitalizations with varenicline compared with nicotine replacement therapy patch over 30 or 60 days after drug initiation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/j.1360-0443.2012.04024.x","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T17:57:34Z","timestamp":1342807054000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Neuropsychiatric events in varenicline and nicotine replacement patch users in the\n M<\/scp>\n ilitary\n H<\/scp>\n ealth\n S<\/scp>\n ystem"],"prefix":"10.1111","volume":"108","author":[{"given":"Tamra E.","family":"Meyer","sequence":"first","affiliation":[{"name":"Department of the Army Office of the Surgeon General Pharmacovigilance Center Falls Church VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lockwood G.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of the Army Office of the Surgeon General Pharmacovigilance Center Falls Church VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suji","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of the Army Office of the Surgeon General Pharmacovigilance Center Falls Church VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Graham","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology Food and Drug Administration Center for Drug Evaluation and Research Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Mosholder","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology Food and Drug Administration Center for Drug Evaluation and Research Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Williams","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology Food and Drug Administration Center for Drug Evaluation and Research Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Moeny","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology Food and Drug Administration Center for Drug Evaluation and Research Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita P.","family":"Ouellet\u2010Hellstrom","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology Food and Drug Administration Center for Drug Evaluation and Research Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinka S.","family":"Coster","sequence":"additional","affiliation":[{"name":"Department of the Army Office of the Surgeon General Pharmacovigilance Center Falls Church VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,18]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Food and Drug Administration (FDA).FDA approves novel medication for smoking cessation.2006. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108651.htm (accessed 15 August 2012) (Archived athttp:\/\/www.webcitation.org\/69w5eyt4Von 15 August 2012)."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.47"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.15.1561"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub5"},{"key":"e_1_2_6_6_1","unstructured":"Food and Drug Administration (FDA).Early communication about an ongoing safety review of varenicline (marketed as Chantix).2007. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm070765.htm (accessed 15 August 2012) (Archived athttp:\/\/www.webcitation.org\/69w64F5mh)."},{"key":"e_1_2_6_7_1","unstructured":"Food and Drug Administration (FDA).Public Health Advisory: important information on Chantix (varenicline).2008. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/PublicHealthAdvisories\/ucm051136.htm (accessed 15 August 2012) (Archived athttp:\/\/www.webcitation.org\/69w81tM0i)."},{"key":"e_1_2_6_8_1","unstructured":"Federal Aviation Administration.Anti\u2010smoking medicine Chantix banned.2011. Available at: http:\/\/www.faa.gov\/news\/updates\/?newsId=56363 (accessed 15 August 2012) (Archived athttp:\/\/www.webcitation.org\/69w89DSsK)."},{"key":"e_1_2_6_9_1","unstructured":"Food and Drug Administration (FDA).Public Health Advisory: FDA requires new boxed warnings for the smoking cessation drugs Chantix and Zyban.2009. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/PublicHealthAdvisories\/ucm169988.htm (accessed 15 August 2012) (Archived athttp:\/\/www.webcitation.org\/69w8TR2DN)."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319180-000000000-00000"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.12.005"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.20.2606"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L661"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.03.007"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.02.001"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.02083.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-0926-8"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100196"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b3805"},{"key":"e_1_2_6_20_1","unstructured":"US Department of Veterans Affairs.Varenicline criteria for prescribing.2011. Available at: http:\/\/www.pbm.va.gov\/CriteriaForUse.aspx (accessed 15 August 2012) (Archived athttp:\/\/www.webcitation.org\/69w8cAMFt)."},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_6_22_1","volume-title":"Drug Information Handbook","author":"Lacy C. F.","year":"2006"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181dbebe3"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj149"},{"key":"e_1_2_6_25_1","unstructured":"LeuvenE. SianesiB.PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching common support graphing and covariate imbalance testing. This version 4.0.3 01oct2010;2003. Software available fromhttp:\/\/ideas.repec.org\/c\/boc\/bocode\/s432001.html accessed 15 August 2012 (Archived athttp:\/\/www.webcitation.org\/69wHPdPy6)."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.01.003"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1360-0443.2012.04024.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1360-0443.2012.04024.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:33:38Z","timestamp":1698626018000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1360-0443.2012.04024.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1360-0443.2012.04024.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1360-0443.2012.04024.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717957100.793461601","asserted-by":"object"}]},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,18]]},"assertion":[{"value":"2012-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}